Alumis Stock Quote ALMS - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

7.45

Bid

6.76

Ask

9.55

Volume

75,787

7.205 Day's Range 7.5199

6.29 52 Week Range 13.50

Market Cap

405.335M

Previous Close

7.44

Open

7.44

Last Trade

7.08

Last Trade Time

Financial Volume

$ 561,433

VWAP

7.408

Average Volume (3m)

140,932

Shares Outstanding

54,407,327

Dividend Yield

PE Ratio

-2.60

Earnings Per Share (EPS)

-2.85

Revenue

Net Profit

-154.99M

Alumis' mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor th... Alumis' mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis, and is currently being evaluated in additional Phase 2 clinical trials in patients with systemic lupus erythematosus (SLE) and non-infectious uveitis, for which we expect to report results in 2026 and by the end of 2024, respectively. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.alumis.com

Headquarters

Dover, Delaware, USA

Founded

Alumis Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ALMS. The last closing price for Alumis was $7.44. Over the last year, Alumis shares have traded in a share price range of $ 6.29 to $ 13.50.

Alumis currently has 54,407,327 shares outstanding. The market capitalization of Alumis is $404.79 million. Alumis has a price to earnings ratio (PE ratio) of -2.60.

Alumis Strengthens Leadership Team with Key Appointments

Jack Danilkowicz appointed as Chief Commercial Officer; bringing extensive experience successfully planning and executing commercial strategies at global biopharmaceutical companies Sara Klein...

Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005

– A-005 was well tolerated and demonstrated ability to cross blood-brain barrier – – Maximal TYK2 inhibition achieved with favorable pharmacokinetic profile in CNS and periphery – – Data support...

Form 8-K - Current report

Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

– Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition – – Continued to advance three clinical...

Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to...

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

28-week data show ESK-001 was generally well tolerated and most patients treated with the top dose of 40 mg twice daily achieved PASI 75Three additional data presentations further support...

Alumis to Participate in Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.9	13.7404580153	6.55	7.79	6.29	183116	6.95990579	CS
4	-1.16	-13.4727061556	8.61	8.835	6.29	146779	7.07344825	CS
12	-4.41	-37.1838111298	11.86	12.16	6.29	140932	8.25177061	CS
26	-5.05	-40.4	12.5	13.11	6.29	143975	10.21823001	CS
52	-5.37	-41.887675507	12.82	13.5	6.29	148104	10.58870899	CS
156	-5.37	-41.887675507	12.82	13.5	6.29	148104	10.58870899	CS
260	-5.37	-41.887675507	12.82	13.5	6.29	148104	10.58870899	CS

ALMS - Frequently Asked Questions (FAQ)

What is the current Alumis share price?

The current share price of Alumis is $ 7.45

How many Alumis shares are in issue?

Alumis has 54,407,327 shares in issue

What is the market cap of Alumis?

The market capitalisation of Alumis is USD 404.79M

What is the 1 year trading range for Alumis share price?

Alumis has traded in the range of $ 6.29 to $ 13.50 during the past year

What is the PE ratio of Alumis?

The price to earnings ratio of Alumis is -2.6

What is the reporting currency for Alumis?

Alumis reports financial results in USD

What is the latest annual profit for Alumis?

The latest annual profit of Alumis is USD -154.99M

What is the registered address of Alumis?

The registered address for Alumis is 3500 S DUPONT HWY, KENT, DOVER, DELAWARE, 19901

What is the Alumis website address?

The website address for Alumis is www.alumis.com

Which industry sector does Alumis operate in?

Alumis operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CAPTCaptiVision Inc	$ 1.024 (133.26%)	245.99M
QNTMQuantum Biopharma Ltd	$ 6.70 (110.69%)	78.56M
LTRYLottery com Inc	$ 0.58 (85.90%)	129.21M
CPIXCumberland Pharmaceutical Inc	$ 3.7801 (77.47%)	18.49M
INKTMiNK Therapeutics Inc	$ 12.08 (53.69%)	350.86k
OMGAOmega Therapeutics Inc	$ 0.1473 (-69.25%)	11.7M
VIRXViracta Therapeutics Inc	$ 0.0352 (-54.76%)	6.33M
CYNCYNGN Inc	$ 0.0708 (-39.44%)	137.27M
UPCUniverse Pharmaceuticals Inc	$ 0.2663 (-36.20%)	1.9M
CSAICloudastructure Inc	$ 12.98 (-31.68%)	57.03k
NVDANVIDIA Corporation	$ 118.65 (1.71%)	247.88M
CAPTCaptiVision Inc	$ 1.024 (133.26%)	245.98M
PLTRPalantir Technologies Inc	$ 103.83 (23.99%)	212.8M
RGTIRigetti Computing Inc	$ 13.71 (1.78%)	150.62M
CYNCYNGN Inc	$ 0.0708 (-39.44%)	134.49M